Global Pulmonary Inflammation Market: Overview
Pulmonary arteries in our body carries
deoxygenated blood from our heart to the lungs. Oxygen is added to the
blood into the lungs and it (blood) returned to the heart through
pulmonary veins. Pulmonary fibrosis is considered as a chronic disease
that can cause swelling and scarring of the alveoli (air sacs) and
interstitial tissues in the lungs. The scar tissue formed in the lungs
can replace healthy tissue and can cause pulmonary inflammation. Due to
pulmonary inflammation our lung becomes stiff that makes breathing very
difficult. Etiology for pulmonary inflammation includes emphysema, lung
cancer, pulmonary fibrosis, embolism, therapeutic radiation, rheumatoid
arthritis and sarcoidosis.
Breathlessness is identified as the most
common symptom of pulmonary inflammation. Dry cough is also considered
as very common symptom of pulmonary inflammation. Possible risk factor
for suffering from pulmonary inflammation includes cigarette smoking,
therapeutic radiation, rheumatoid arthritis and sarcoidosis. Various
diagnosis test performed for detection of the pulmonary inflammation
includes chest X-ray, pulmonary function test (spirometry),
bronchoalveolar lavage test and lung biopsy test. Canadian Lung
Association stated that, corticosteroid medication is identified as the
most effective treatment for pulmonary inflammation under supervision of
a registered medical practitioner. Moreover, it has also stated that,
sometimes oxygen therapy is required in order to treat breathlessness.
Global Pulmonary Inflammation Market: Drivers and Restraints
Increasing cigarette smokers and growing
prevalence of cancer is considered as a major driving factor of the
global pulmonary inflammation treatment market. Moreover, rising
prevalence of rheumatoid arthritis cases also accentuates the global
market demand of pulmonary inflammation treatment. As an instance, the
World Health Organization (WHO) published in 2014, that worldwide 8.2
million people died of cancer in the year 2012. In 2013, American Cancer
Society (ACS) published that, around 300,000 men and 276,000 women died
due to cancer in 2012 in the U.S. Likewise, emphysema (COPD) is also
considered as a major factor that can cause pulmonary inflammation among
the global population at a significant rate. Emphysema is mostly caused
due to cigarette smoking. According to the Centers for Disease Control
and Prevention (CDC), in 2012, North America accounted for the highest
number of COPD cases in the world. Moreover, according to the Centers
for Disease Control and Prevention (CDC), an estimated 67 million people
in the U.S. above 18 years of age would be diagnosed with arthritis by
2030.
Thus, rising prevalence of arthritis and
cancer would accentuate the global market demand of pulmonary
inflammation treatment. However, technical complexity and high cost
associated with diagnosis procedure of pulmonary inflammation might
restrict the global market demand of pulmonary inflammation to some
extent.
Global Pulmonary Inflammation Market: Regional Analysis
North America and Europe was observed to
be the largest pulmonary inflammation market due to major market players
are based in these regions. Moreover, technological advancement in
diagnostic test and strong demand of diagnostic test would also account
for the market growth in these regions. In addition, favorable
initiative taken by the federal government also accounted for the
pulmonary inflammation treatment market growth in North American and
European regions.
Similarly, Asia-Pacific is considered as
an untapped market due to lack of proper diagnostic facilities in some
Asian countries. Asian market growth will be fuelled by the presence of
untapped opportunities due to extensive increase in the healthcare
infrastructure (healthcare cost, healthcare facility and healthcare
budget). Similarly, Asia-Pacific is considered as an emerging market due
to growing market penetration in this region. Rest of the world (RoW)
holds fourth position in the global pulmonary inflammation treatment
market due to poor economic and health condition in most of the African
countries.
Global Pulmonary Inflammation Market: Companies Mentioned in the Report
Major market players involved
manufacturing the therapeutic product of pulmonary inflammation
treatment products and contributing the global market share includes
Pharmaxis Limited, InDex Pharmaceuticals AB, Resolvyx Pharmaceuticals,
Inc., Idera Pharmaceuticals, Inc., Asmacure Ltee, Celtaxsys, Inc., among
others.
No comments:
Post a Comment